Although blockade of the PD-1/PD-L1 interaction has transformed NSCLC therapy, a substantial fraction of patients does not respond, partially due to heterogeneity in PD-L1 isoform expression. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.